Skip to main content
. Author manuscript; available in PMC: 2017 Mar 7.
Published in final edited form as: Prostate Cancer Prostatic Dis. 2016 Jan 12;19(2):168–173. doi: 10.1038/pcan.2015.61

Figure 2.

Figure 2

Conventional multiparametric-magnetic resonance imaging components and restriction spectrum imaging-magnetic resonance imaging (RSI-MRI) as used for targeting biopsy. (a) 4+3 Gleason score (GS) prostate cancer (PCa) in the right anterior mid central gland, (b) 4+4 GS PCa in the right posterior base peripheral zone, (c) 3+4 GS PCa in the left posterior mid peripheral zone. In these cases, RSI-MRI more conspicuously demarcates PCa for targeted biopsy than T2, dynamic contrast enhancement or conventional diffusion-weighted imaging techniques as confirmed by post-prostatectomy whole-mount pathology.